Hematopoietic stem cell (HSC) gene therapy has the potential to cure many genetic, malignant and infectious diseases. We have shown in a nonhuman primate HSC gene therapy and transplantation model that the CD34 + CD90 + CD45RAcell fraction was exclusively responsible for multilineage engraftment and hematopoietic reconstitution. Here we establish the translational potential of this HSC-enriched CD34 subset for lentivirus-mediated gene therapy.
INTRODUCTION
Hematopoietic stem cell (HSC)-mediated gene therapy or editing for the treatment of hematologic disease is commonly performed with single-marker purified CD34 + cells. However, it is well-established that CD34 + cells are a heterogeneous mix of predominantly lineage-committed progenitor cells containing only very few true HSCs with long-term multilineage engraftment potential (1, 2) . Moreover, the proportion of true HSCs is variable across individuals, requiring at least 2 x 10 6 viable CD34 + cells per kg of body weight to meet safety and feasibility standards.
This results in excessive use of costly reagents (e.g. lentiviral vectors or nucleases) for gene transfer to reliably target HSCs (3) (4) (5) (6) (7) (8) (9) . Moreover, the efficiency of gene-modification seen ex vivo does not correlate with the in vivo engraftment of modified cells commonly stabilizing at a significantly lower frequency (4, 10). These major hurdles significantly limit the broad availability of this very promising technology as a potential cure for many patients.
HSC gene therapy and transplantation would benefit from the ability to isolate, target, and modify a more HSC-enriched subset that provides short-term reconstitution as well as long-term multilineage engraftment. Availability of a refined target would overcome all currently existing limitations simultaneously: 1) greatly reduce the amount of modifying reagents needed for manufacturing, 2) result in more reliable genetic-modification of HSCs, and 3) increase the predictability of transplant success in vivo.
Within the last four decades, a plethora of cell surface markers have been described for the identification and purification of human HSCs (1, (11) (12) (13) (14) (15) . Similarly, a great variety of HSCenrichment strategies has been proposed for gene therapy approaches. Some of the most promising candidate HSC-enrichment strategies include the purification of the CD38 low/- (16, 17) , CD133 + (18) , or CD90 + (19) Here, we applied up-to-date read-outs (in silico, in vitro, and in vivo) for a systematic and objective side-by-side comparison of candidate HSC-enrichment strategies with the goal to identify the most refined HSC-enriched target for gene therapy and editing.
RESULTS

scRNA-seq objectively identifies committed and immature HSPCs
Single cell transcriptome analysis has proven useful in determining the heterogeneity of complex cell populations (20) . Here, we used single-cell RNA sequencing (scRNA-seq) on the 10X Genomics chromium platform to assess the heterogeneity of CD34 + hematopoietic stem and progenitor cells (HSPCs). To identify transcriptionally distinct CD34 subsets and generate a reference map of human HSPCs, we sequenced CD34 + cells from steady-state BM (ssBM) of two healthy human individuals (Supplemental Table 1 ). The scRNA-seq data was analyzed using two different methods of dimensional reduction: t-distributed stochastic neighbor embedding (tSNE) and principle component analysis (PCA).
The tSNE plot showed multiple areas of cell-aggregated clusters (Figure 1A) . The overlay of gene expression data onto the tSNE plot identified clusters of cells upregulating genes associated with lymphoid, myeloid, and/or erythroid commitment (Figure 1B) . Cells with low or absent expression of lineage-specific genes demonstrated upregulation of genes associated with primitive HSPCs. Upregulation of cell cycle associated genes were found primarily in regions with transcriptionally lineage-committed cells.
Next, scRNA-seq data was visualized by PCA to preserve gene expression patterns and avoid the randomness of clustering. PCA analysis resulted in a two-prong hierarchical arrangement of cells ( Figure 1C) . In comparison to the clusters in the tSNE plot, cells upregulating genes for lymphoid, myeloid, and erythroid commitment were found along both arms, whereas more immature progenitor cells were located at the intersection in the apex of the scRNA-seq dataset (Figure 1D) . Visualization of scRNA-seq data using either tSNE or PCA were highly reproducible among biological replicates with only minor differences in the quantitative representation of transcriptionally-distinct CD34 sub-clusters (Supplemental Figure 1) .
Manual identification of scRNAseq clusters assessing the expression of representative genes was confirmed using the Seurat un-supervised graph-based clustering tool (21) . Seven transcriptionally distinct groups of single cells were identified within CD34 + cell populations (Supplemental Table 2 ). Clusters were mapped onto both the tSNE (Figure 1E Almost identical to our manual assessment, genes associated with primitive HSPCs were predominantly expressed in cluster 1. Increased expression of genes for lymphoid, myeloid, and erythroid differentiation were observed in clusters 2 and 3, clusters 4 and 5, and clusters 6 and 7, respectively.
In summary, scRNA-seq allows for a reliable and reproducible assessment of the transcriptional heterogeneity within CD34 + HSPCs from ssBM. Most importantly, visualization of single-cell data using either tSNE or PCA are interchangeable and provide a reliable reference map.
CD90 + CD45RAcells are the most refined target for HSC gene therapy
Multilineage long-term engraftment and BM reconstitution is driven by CD34 + CD90 + HSPCs in the pre-clinical nonhuman primate (NHP) stem cell transplantation model (19) or human CD34 + CD38 low/cells in the mouse xenograft model (22, 23) . To evaluate the translational potential of the CD34 + CD90 + phenotype, we compared this subset to alternative HSC-enrichment strategies including CD34 + CD133 + (18) and CD34 + CD38 low/- (16, 17) HSPCs.
We first analyzed the phenotype of sorted subpopulations for contaminating cell types.
The CD133 + subpopulation showed approximately 50% enrichment of CD38 low/but only 27% of the CD90 + subset (Figure 2A and Supplemental Figure 3 ). Purified CD38 low/cells were markedly enriched for CD133 + (78%) and CD90 + (49%) cells but still contained a significant proportion of CD90 -HSPCs (51%). CD90 + cells demonstrated more than 86% enrichment of CD133 + as well as CD38 low/-HSPCs. Across nine different healthy donors, enrichment of the CD133 + subset would be predicted to reduce the target cell count for HSC gene therapy by 58% Next, we looked at the gene-expression of CD34, CD133, CD38, and CD90 in the reference map ( Figure 2D and Supplemental Figure 4A ). CD34 expression was detectable in all clusters, with a gradual increase towards the area at the top of the plot associated with more primitive HSPCs. In good agreement to previous publications (1, (24) (25) (26) (27) , CD133 mRNA expression was restricted to transcriptionally committed lympho-myeloid progenitors as well as immature HSPCs (clusters 1-5). CD38 expression was scattered throughout the reference map and showed no obvious association or absence in distinct clusters. Surprisingly, CD90 expression was undetectable in both donors.
Since sole assessment of mRNA expression was insufficient for an objective comparison of phenotypical CD34 subsets, we sort-purified CD133 + , CD38 low/-, and CD90 + cell fractions (Supplemental Figure 3) , performed scRNA-seq, and overlaid the resulting data onto the CD34 PCA plot (Figure 2E) . Similar to the observed expression pattern, sort-purified CD133 HSCPs exclusively colocalized with lympho-myeloid and more primitive HSPCs. Sort-purified CD38 low/cells predominantly overlaid with cluster 1 of the reference map, with individual cells spreading into both the lympho-myeloid as well as the erythroid branch. Surprisingly, mapping of sortpurified CD90 + cells was almost indistinguishable from CD38 low/cells (Figure 2E and Supplemental Figure 4B ). Similar to CD38 low/-HSPCs, CD90 sorted cells demonstrated a significant enrichment of immature HSPCs (cluster 1), as well as depletion of lympho-myeloid as well as erythroid primed progenitors (Figure 4B, Supplemental Figure 4B ).
In summary, purification of CD90 + HSPCs yielded the greatest reduction of target cells for HSC gene therapy in comparison to CD133 + or CD38 low/subsets. While the phenotypical comparison of these HSC enrichment strategies demonstrated reproducible differences, CD38 low/--and CD90 + -sorted subpopulations were transcriptionally indistinguishable by scRNAseq.
CD90 + HSPCs are transcriptionally unique
Objective comparison of CD38 low/and CD90 + HSPC subsets by scRNA-seq is significantly diminished by the mRNA capture efficiency (28) (29) (30) (31) . To increase the sensitivity for subtle transcriptional difference in between the CD90 + and CD38 low/phenotypes, we performed bulk-RNA-seq on purified CD34 subsets from the ssBM of two healthy donors. Bulk RNA-seq data was plotted onto our CD34 scRNA-seq reference map to determine transcriptional similarities/differences as well as donor to donor variance of sorted subsets. ssBM CD34 + cells were initially subdivided and sorted based on the following gating strategy. For CD34 + CD90 + HSPCs (Population a) the cells were gated on CD45RA and CD90 (19) (Figure 3A and Supplemental Figure 5 ). Assessing CD133 expression, CD34 + CD90 -HSPCs were further subdivided into CD45RA -CD133 + (Population b), CD45RA + CD133 + (Population c) and CD45RA -CD133 low/-(Population d) HSPCs (26, 32, 33) . For comparison with classical strategies using CD38, CD34 + CD38 low/cells (Population e) were subdivided into CD34 + CD38 low/-CD90 + (Population f) and CD34 + CD38 low/-CD90 -(Population g) subsets (16, 17, 27) .
Consistent with the reported functional assessment of these phenotypically-defined CD34 subsets (16, 17, 19, 26, 27, 32, 33) , we observed upregulation of lymphoid genes (JCHAIN, To confirm this manual assessment, we mapped the bulk-RNA-seq data onto our CD34 scRNAseq reference map ( Figure 3C ). Here we found similar distribution to previously defined clusters with minimal variability, likely attributed to differences in donors ( Figure 2F) In conclusion, bulk RNAseq increases the sensitivity for low-expressed genes and enables the comparison of CD34 subsets with only subtle differences in transcriptomics. Most importantly, bulk RNA-seq highlights the reproducibility of transcriptional patterns within CD90 + HSPCs, whereas CD38 low/cells contain a significant proportion of erythro-myeloid primed CD38 low/-CD90progenitor cells increasing the heterogeneity in the transcriptional signature.
GCSF-mobilized CD90subsets are transcriptionally similar to immature CD90 + HSPCs
Granulocyte-colony stimulating factor (GCSF)-mobilized CD34 + HSPCs are the most frequently used cell source for HSC gene therapy approaches. To evaluate the conservation of transcriptional patterns in phenotypically-defined CD34 subsets across sources, bulk RNA-seq data of sort-purified HSPC subsets (Populations a-d) from two GCSF-mobilized donors was projected onto our ssBM-based reference map.
Similar to ssBM, key regulators for lympho-myeloid and erythroid as well as immature GCSF-mobilized CD34 subsets were upregulated in Populations c, d, and a, respectively (Supplemental Figure 6A , Supplemental Table 4 ). As expected, GCSF-mobilized HSPCs from In summary, GCSF-mobilized CD34 subsets can be mapped onto the ssBM scRNA-seq reference. While bulk RNAseq data of immature as well as committed progenitor cells localized within the expected clusters, CD34 + CD90 -CD133 + CD45RA -HSPCs from GCSF-mobilized donors were transcriptionally almost identically to the HSC-enriched CD34 + CD90 + subset.
BM reconstitution potential is restricted to CD34 + CD90 + cell fractions
Pre-clinical experiments in the NHP and mouse showed that GCSF-primed CD34 + CD90 + HSPCs were solely responsible for reconstitution of the BM stem cell compartment (19, 35) . To validate the engraftment potential of this HSC-enriched phenotype in humans, CD34 + cells from healthy human GCSF-mobilized donors were sort-purified into Populations a-d and transplanted into sublethally irradiated adult NSG mice. Figure 9G ).
In summary, mouse xenograft experiments confirm enrichment of primitive human HSPCs
with multilineage engraftment and BM reconstitution potential in the CD34 + CD90 + phenotype (Population a). Furthermore, CD34 + CD90 -CD133 + CD45RA -HSPCs (Population b) contain lowlevel multilineage engraftment potential but lack the ability to recover the entire stem cell compartment.
Small molecules slightly enhance gene-modification of the CD90 subset
A variety of transduction enhancers have been reported for the use on human CD34 + HSPCs to boost the efficiency of gene-modification in long-term engrafting HSCs (36) (37) (38) . The majority of studies were performed with umbilical cord blood (UCB)-derived CD34 + HSPCs, a less frequently used cell source for HSC gene therapy. Here, we tested some of the recently reported small molecules on GCSF-mobilized CD34 + cells and specifically determined the frequency of GFPexpression in the HSC-enriched CD34 + CD90 + subset characterized above (Figure 5A) .
Bulk CD34 + cells were purified on the CliniMACS Prodigy (day 1), stimulated in HSPC culture medium overnight, and gene-modified (MOI5x1) at day 2 in either regular culture medium without additional additives (Tsd Control), on Retronectin-coated plastic (Retronectin) or in the presence of PGE2, UM171, and a combination of SR1 (36, 39) , UM171 (37), as well as Ly2228820 (38, 40, 41) (SULy). Virus and additives were removed after 2 hours (day 2), cells were cultured in HSPC medium for 3 days to allow GFP expression, and the phenotypical composition of cells then assessed flow-cytometrically on day 5. Short-term exposure of bulk CD34 + cells with the small molecules did show no impact on the average frequency of HSCenriched CD34 + CD90 + cells in comparison to the non-transduced control (NT Control) ( Figure   5B ,C and Supplemental Table 9 ). Similarly, no obvious effect of the small molecules could be seen on the transduction efficiency in bulk CD34 + cells. However, presence of UM171 and SULy did promote a slight increase in the average expression of GFP within HSC-enriched CD34 + CD90 + HSPCs (Figure 5C and Supplemental Table 9 ).
To assess the impact of the gene-modification and culture conditions on the functional properties, bulk CD34 + cells as well as HSC-enriched CD34 + CD90 + HSPCs were introduced into CFC assays on day 3 (Figure 5D and Supplemental Table 9 ). Unexpectedly, a significant increase in the total CFC potential was seen across all gene-modified bulk CD34 + cells in comparison to non-transduced cells. However, no impact on the overall colony-forming ability and composition was seen comparing the individual conditions or specifically analyzing the CD34 + CD90 + subset.
In summary, short-term exposure of adult GCSF-mobilized CD34 + cells with PGE2, UM171, and the combination of multiple small molecules (SULy) does slightly enhance the transduction efficiency within CD34 + CD90 + cells without impacting the functional properties.
However, the reported improvement of transduction on UCB-derived CD34 + cells could not be fully reproduced in GCSF-mobilized HSPCs.
Sort-purification increases the transduction efficiency in HSC-enriched CD90 + cells
While transduction enhancers are proposed to increase the efficiency of lentivirus-mediated gene transfer in CD34 + cells (36) (37) (38) , these represent additional reagents which add to cost, complexity and preclinical safety determinations needed for gene therapy, while still requiring large amounts of expensive clinical-grade viral vector. To overcome this limitation, we next evaluated the feasibility of a flow-cytometry based sort-purification strategy for the large-scale enrichment and direct targeting of CD90 + cells. (42) . Leukapheresis products yielded on average 2.56×10 8 CD34 + cells with a purity greater than 93.5±1.9%. Donor #4 insufficiently mobilized CD34 + cells and was excluded from the study.
Sort-purification of CD90 + HSPCs was performed comparing the jet-in-air sorter FX500 from Sony with the cartridge-based closed-system sorter MACSQuant Tyto from Miltenyi Biotech ( Figure 6A) . Sorted CD90 + cell fractions on both machines showed no significant phenotypical or quantitative differences. They both reached an average of 79.5±6.9% (Sony) and 77.1±5.5%
(Tyto) purity with a yield of 52.3±9.6% and 49.9±11.1%, respectively (Figure 6B,C) . Of special interest for HSC gene therapy, the average fold-enrichment of target cells was greater than 29.7±5.7-fold on the Sony sorter and up to 37.2±7.3-fold on the Tyto (Figure 6C) . To determine whether the sort-purification impacted the differentiation potential of HSC-enriched CD34 subsets, cells were introduced into CFC assays. Sort-purified cell fractions did not demonstrate any differences in the total nor compositional CFC potential compared to unprocessed cells ( Figure   6D ).
Next, sorted CD90 + as well as bulk CD34 + cells were transduced with a lentivirus encoding for GFP according to our clinically approved CD34-mediated gene therapy protocol (43, 44) . Five days post-transduction, the gene-modification efficiency in the CD90 + subset of bulk-transduced CD34 cells reached 16.5±3.4% (SEM), whereas 2.3-fold (Tyto: 38.1±5.5%, SEM, p=0.012) and
3.1-fold (Sony: 51.9±5.8%, SEM, p=0.006) higher frequencies of GFP were seen in the sortpurified CD90 + cell fractions ( Figure 6E ). Despite significant differences in the gene-modification efficiency, no significant increase in the overall MFI of GFP was observed transducing purified CD90 + cells (Figure 6E) . Gene-modified cells were introduced into CFC assay showing no significant quantitative and qualitative differences (Figure 6F) . Finally, individual colonies were extracted to determine the gene-modification efficiency within erythro-myeloid colonies as well as to precisely quantify the vector copy number (VCN). No obvious differences were found in the expression of GFP within CFCs from all three conditions (Figure 6G) . Similar to the MFI of GFP, almost identical VCNs were observed in all setting (Figure 6H) .
In summary, the sort-purification of CD90 + cells is technically feasible and does not impact the cells phenotypical and functional properties. Most importantly, purification of CD90 + cells reduces the number of target cells and simultaneously improves the efficiency of lentivirusmediated gene-transfer without increasing the MFI as well as VCN and without the need for additional transduction enhancers.
Improved in vivo engraftment of sort-purified and gene-modified CD90 + HSPCs
Regardless of high gene-modification efficiency ex vivo, the frequency of long-term in vivo engraftment of modified cells is often both unpredictable and, in many studies, significantly lower compared to values determined during quality control of the infusion product (10, 45, 46) . To compare the multilineage long-term engraftment potential of gene-modified bulk CD34 + with sortpurified CD90 + HSPCs, cells were transplanted into sublethally irradiated adult NSG mice. Of note, in order to mimic the average percentage of CD90 + cells within bulk CD34 + cell fractions (see Figure 2B ) mice transplanted with sort-purified CD90 + cells received 1/10 th the cell number compared to mice transplanted with bulk CD34 + cells.
Multilineage engraftment of human cells in the PB of transplanted mice was followed longitudinally by flow-cytometry (Figure 7A, Supplemental Figure 10A ). Mice transplanted with bulk CD34 + as well as Tyto-sorted CD90 + cells showed persisting levels of human engraftment, whereas human chimerism in the vast majority of mice receiving Sony-sorted CD90 + HSPCs gradually declined towards the end of study. Similar trends in the overall frequency of human multilineage engraftment were seen at the day of necropsy in the BM, spleen, and thymus. The greatest frequency of human chimerism was found in mice transplanted with bulk CD34 + and Tyto-sorted CD90 + HSPCs followed by Sony-sorted CD90 + cells (Figure 7B Lentiviral-mediated delivery of GFP enabled us to flow-cytometrically follow the frequency of gene-modification longitudinally in the PB as well as at the day of necropsy in tissues.
Consistent with the efficiency of gene-modification we saw ex vivo (Figure 6E) , a 2-to 3-fold higher frequency of GFP + human cells was seen in the PB and tissues of animals receiving sortpurified CD90 + cells compared to bulk CD34 + cells (Figure 7C,D) . The frequency of genemodification in the PB of animals transplanted with sort-purified CD90 + cells remained consistent throughout the follow-up, whereas in animals receiving gene-modified bulk CD34 + cells two patterns were observed; human cells 1) either gradually lost the gene-modification leveling out at about 10-15% or 2) started to show a rapid increase in GFP + human cells up to almost 80% towards the end of study.
Next, we comprehensively analyzed the BM stem cell compartment of engrafted mice.
Mice transplanted with bulk CD34 + and Tyto-sorted CD90 + cells demonstrated significantly greater engraftment of human CD34 + and CD34 + CD90 + cells compared to Sony-sorted CD90 + HSPCs (Figure 7E) . Most importantly, the frequency of gene-modified CD90 + cells was in average 2-to 3-fold higher in mice engrafted with sort-purified and gene-modified CD90 + compared to bulk CD34 + HSPCs. Finally, we introduced BM-resident human CD34 + into CFC assays to test the maintenance of erythro-myeloid differentiation potentials (Figure 7F) . After transplantation of either bulk CD34 + or Sony-sorted CD90 + in only two mice, each phenotypical CD34 + cell gave rise to colonies, whereas in 8 out of 9 cases erythro-myeloid colonies were seen in mice receiving Tyto-sorted CD90 + cells.
In summary, gene-modification of sort-purified CD34 + CD90 + cells on the Tyto does not alter the multilineage long-term engraftment potential of human HSPCs in the mouse xenograft model. Most importantly, gene-editing efficiencies observed ex vivo successfully translated into the in vivo transplant and remained stable throughout the long-term follow-up.
DISCUSSION
Here, we show that the enrichment of the human CD34 + CD90 + population has the potential to overcome current limitations of HSC gene therapy. Sort-purification of this HSC-enriched CD34 subset resulted in up to 40-fold reduction of target cells and consequently significant savings of costly reagents (here lentiviral vectors). Most importantly, sole purification of this phenotype improved the gene-modification efficiency of HSCs with long-term in vivo engraftment potential up to 3-fold perfectly reflecting the ex vivo assessment, enhancing the predictability of HSC gene therapy, and improving the long-term stability of modified cells at high levels. Thus, CD34 + CD90 + HSCs demonstrate the most refined target population for HSC gene therapy and transplantation.
In order to systematic and objectively compare human candidate HSC-enriched target cell populations for HSC gene therapy, we here combined up-to-date transcriptional, phenotypical, and functional read-outs. We initially purified previously reported HSC-enriched cell populations as well as our recently defined CD34 + CD90 + subset and performed high-throughput scRNA-seq analysis. The phenotypical heterogeneity, the relationship in between subsets, as well as the quantitative reduction of target cells for each CD34 subset was evaluated using multi-color flowcytometry. In addition, comprehensive mouse xenograft assays were performed to evaluate the multilineage engraftment and BM reconstitution potential of human CD34 + subsets. In this comprehensive side-by-side comparison, we observed the greatest reduction of target cells in the CD34 + CD90 + cell fraction without compromising the multilineage engraftment and BM reconstitution potential in mouse xenograft transplants. Furthermore, scRNA-seq data showed that CD34 + CD90 + cells are almost entirely depleted for lineage-committed progenitor cells, while phenotypically, transcriptionally, and functionally primitive HSPCs are markedly enriched.
After this comprehensive comparison, bulk CD34 + cells from GCSF-mobilized PBSCs, the most common cell source for HSC gene therapy, were gene-modified in the presence of previously reported small molecule transduction enhancers to assess the gene-modification in the transcriptionally, phenotypically and functionally most primitive HSC-enriched CD34 + CD90 + subset. In contrast to previous literature describing significantly enhanced transduction efficiency in umbilical cord blood (UCB)-derived CD34 HSPCs, only minor improvement of genemodification could be observed in the CD34 + CD90 + cell fraction from GCSF-mobilized PBSCs.
Finally, we compared two good manufacturing practice (GMP)-compatible flow-cytometry assisted cell sorting (FACS) platforms for the sort-purification and gene-modification of HSCenriched CD34 subsets. Purity and yield of sorting, gene-modification efficiency, as well as maintenance of stem cell features was confirmed by flow-cytometry with in vitro colony-forming cell assays and mouse xenograft transplants. We demonstrate that direct transduction of sortpurified CD34 + CD90 + cells significantly reduced gene-modifying reagents and, at the same time, enhanced the gene-modification efficiency without compromising the long-term multilineage engraftment potential.
These findings are all in line with our recently performed competitive reconstitution studies in the NHP to identify a refined target cell population for HSC gene therapy and transplantation (19) . In our previous study, we reported the CD34 + CD90 + phenotype to be exclusively responsible for both rapid short-term as well as robust long-term hematopoietic reconstitution. Here we show that human multilineage engraftment potential with full recovery of the BM stem cell compartment is similarly restricted to CD34 + CD90 + HSPCs, whereas CD34 + cells that lost CD90 expression lack full multilineage xenograft reconstitution potential. This finding mirrors previous publications describing the enrichment of human HSCs within CD90-expressing CD34 subsets. The first CD90-mediated isolation of human HSCs from fetal BM, adult BM, and cytokine-mobilized stem cells was reported in the 1990s (11, 47) . Thereafter, lin -CD34 + CD90 + subsets were shown to be enriched for long-term culture-initiating cells (LTC-ICs) with thymus engraftment potential in the SCID mouse model (11, 47) . However, alternative CD90/Thy-1 antibody clones (F15 421-5 and GM201) were used at this time that recognized a significantly higher expressed CD90 variant on up to 60% of cytokine-mobilized CD34 + cells (11) . Refining the phenotype with additional cell surface markers, switching to the currently used CD90 clone 5E10, and using an improved mouse HSCs, whereas HSPCs lacking CD90 demonstrate limited engraftment potential and do not reexpress or recover the HSC-enriched CD90 + subset. Adding to this, we re-validated findings from the 1990s that employed the commonly used CD90 antibody clone 5E10, which showed that CD34 + CD90 + HSPCs from GCSF-mobilized leukapheresis products, the most commonly used stem cell source for HSC gene therapy and transplantation, exclusively contain primitive HSCs with multilineage engraftment and BM reconstitution potential.
Recent studies aiming to refine the target for HSC gene therapy and transplantation combined flow-cytometry with functional in vitro and/or in vivo read-outs (16, 17) . Here, we additionally applied single-cell as well as bulk RNA sequencing to comprehensively compare the CD34 + CD90 + phenotype with alternative HSC-enrichment strategies. In contrast to most approaches performing transcriptomics (48) (49) (50) , we initially performed scRNA-seq on CD34 + cells to build a detailed and comprehensive reference map rather than using historically defined human CD34 subsets for comparison. This strategy allowed us to define transcriptionally distinct clusters and perform an unbiased assessment of the expression profile in these clusters. Furthermore, we were able to determine the reproducibility of scRNAseq for CD34 + HSPCs and ultimately establish a baseline for the comparison of phenotypically defined HSC-enriched cell fractions. Having this baseline further enabled us to objectively compare scRNA-seq data from different donors as well as reliably map sort-purified CD34 subsets. Most importantly, this strategy provided the foundation to overlay scRNA-seq with bulk RNAseq data from multiple donors without any computational correction or manipulation of the dataset for donor-, batch-, source-or preparationdependent variability. Interestingly, we were not able to reliably determine transcriptional differences between CD34 + CD90 + and CD34 + CD38 low/-HSPCs by scRNA-seq. Using the 10x scRNA-seq V2 platform, we were unable to determine transcriptionally-distinct and meaningful clusters or define more detailed hierarchical structures within either subset. Similar to previous reports on Lin -CD34 + CD38 low/cells describing a Continuum of LOw-primed UnDifferentiated (CLOUD) cells without hierarchical structures (48) (49) (50) (51) , CD34 + CD90 + and CD34 + CD38 low/-HSPCs were indistinguishable even though CD38 low/cells were displaying clear differences in their phenotypical composition. Platform-dependent limitations in the mRNA capturing efficiency (31), technical noise (52) , and low-level expression of key genes currently limit the ability to reliably distinguish differences in RNA expression (49) required to identify cell subsets with short-and long-term engraftment potential within the CD34 + CD90 + phenotype.
Despite the current limitation in scRNA-seq, our approach clearly shows that purified CD34 + CD90 + as well as CD34 + CD38 low/-HSPCs are similarly depleted for transcriptionally lineage-committed progenitor cells. However, combining phenotypical, quantitative, and transcriptional data, the CD34 + CD90 + subset was determined to have the greatest overall reduction of target cells. With an average 12.5-fold reduction in total cells compared to a 5.8-fold for the CD34 + CD38 low/subset, isolation and targeting of CD34 + CD90 + HSPCs significantly increases the feasibility of currently existing HSC gene therapy approaches. Most importantly, transplantation of purified CD34 + CD90 + HSPCs did not compromise the multilineage engraftment potential and BM reconstitution capacity of CD34 subsets from GCSF-mobilized leukapheresis products.
Particularly important for the application of HSC gene therapy as a routine treatment option, we have successfully demonstrated that the large-scale sort-purification of our recently identified HSC-enriched CD90 + subset is technically feasible and significantly reduces the target cell number as well as costs for HSC gene therapy. In comparison to small molecule mediated approaches where bulk CD34 + cells are used, only minor improvement in the transduction efficiency of CD34 + CD90 + cells could be seen and therefor no reduction of modifying agents and improvement of feasibility would be achieved. CD34 + CD90 + cells can be efficiently purified using either the Sony SH800S clean-room dependent droplet-cell sorter or the fully-closed, portable MACSQuant Tyto from Miltenyi without any significant differences in the purity and yield of cells.
However, more comprehensive follow-up studies will be required to further investigate the biological impact of both cell-sorting strategies on the multilineage engraftment potential as well as the efficiency of gene-modification. Specific analysis of stress-mediated responses as well as activation of cell cycle pathways may help to explain the observed differences in the frequency of gene-modification and long-term engraftment seen comparing both systems.
Most surprisingly, we found that the sort-purification CD34 + CD90 + cells significantly increased the transduction efficiency of HSCs with multilineage long-term engraftment potential compared to gold standard CD34 + cells. In particular, the observation that the gene-modification efficiencies determined in culture directly translate into the frequency of gene-modification in vivo will help to increase consistency of quality in stem cell products and ultimately make HSC gene therapy applications more predictable. These findings should have important implications for currently available as well as future HSC gene therapy and gene editing protocols hence only minimal changes in procedures are require for the purification of CD34 + CD90 + cells. Isolation of this HSC-enriched phenotype will allow more targeted gene modification, allow a more controlled vector copy number without the application of small molecule transduction enhancer, and thus likely reduce unwanted off target effects.
Application of this HSC-enriched subset will require the implementation of additional processing steps into existing clinical protocols. While the sort-purification will generate further expenses, costs performing these steps will be easily compensated by the 30-to 40-fold savings in expensive modifying reagents. Gene therapy vectors are currently estimated to be the biggest hurdle in terms of large-scale production and by far the dominating cost factor limiting the routine application of HSC gene therapy (7) (8) (9) . Our HSC-targeted gene therapy strategy will help to overcome both bottlenecks at the same time: a single large-scale virus production can be used for up to 30 patients preventing the shortage of GMP-grade vectors; at the same time, modifying reagents will no longer be the major factor for the price determination in HSC gene therapy.
Availability of new sorting technology for GMP-grade closed-system cell sorting of human HSCs (53) in combination with our HSC-enriched target population will bring HSC gene therapy a significant step closer towards a feasible routing application.
In summary, this study describes a human HSC-enriched cell population with unique phenotypical, functional, and transcriptional features. Isolation of these HSC-enriched CD34 + CD90 + HSPCs has the potential to improve the targeting efficiency of current clinical HSC gene therapy and editing applications, and also reduce toxicity from potential off-target modifications. Conservation of this HSC-enriched phenotype among different human stem cell sources and in the pre-clinical NHP model (19) further highlights its biological relevance. Speciesindependent similarities of engraftment patterns in mouse xenograft (human) and autologous NHP transplants (19, 27) , as well as robust long-term multilineage engraftment with more than two years of follow-up in the NHP (19) are promising indicators for a successful clinical translation of this HSC-enrichment strategy. Finally, this stem cell selection strategy may also allow efficient and effective depletion of donor T cells in the setting of allogeneic stem cell or organ transplantation.
MATERIALS AND METHODS
Cell sources and CD34 + enrichment. Fresh, whole BM in sodium heparin for single cell RNA sequencing was purchased from StemExpress (Folsom, CA). GCSF-mobilized leukapheresis collections were purchased from the Co-operative Center for Excellence in Hematology (CCEH) at the Fred Hutchinson Cancer Research Center. All human samples were obtained after informed consent according to the Declaration of Helsinki stating that the protocols used in this study have been approved by a local ethics committee/institutional review board of the Fred Hutchinson Cancer Research Center. Human CD34 + cells from steady-state BM and GCSFmobilized leukapheresis collections were harvested and enriched as previously described (19, 42) . Enrichment of CD34 + cell fractions was performed according to the manufacturer's instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). (43, 54) . Colonies were scored after 12 to 14 days, discriminating colony forming unit-(CFU-) granulocyte (CFU-G), macrophage (CFU-M), granulocyte-macrophage (CFU-GM) and burst forming unit-erythrocyte (BFU-E). Colonies consisting of erythroid and myeloid cells were scored as CFU-MIX. efficiency and vector copy number (VCN) . To measure the transduction efficiency and vector copy number, at least 80 colonies were picked for each condition. Genomic DNA was isolated by incubating tubes at 95°C for 2 h on a thermal cycler.
Flow cytometry analysis and FACS.
Measurement of transduction
Crude DNA preparations were then subjected to PCR using LV-specific primers (Fwd: 5' AGAGATGGGTGCGAGAGCGTCA 
DATA AND MATERIALS AVAILABILITY
All original RNAseq data were uploaded to the NCBI database. The BioProject Accession code is available upon request. Supplemental Table 10 ). 
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